Apoptotic effects of high-dose rapamycin occur in S-phase of the cell cycle

Cell Cycle

Volumn 14, Issue 14, 2015, Pages 2285-2292

  Saqcena, Mahesh ^a,c   Patel, Deven ^a   Menon, Deepak ^a   Mukhopadhyay, Suman ^a   Foster, David A ^a,b  

^a CITY UNIVERSITY OF NEW YORK   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cell cycle; Glutamine; MTOR; Rapamycin; Synthetic lethality

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; GLUTAMINE; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MEVINOLIN; MUTANT PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE B; RAPAMYCIN; SERINE; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; CHROMONE DERIVATIVE; MORPHOLINE DERIVATIVE; MTOR PROTEIN, HUMAN; RAS PROTEIN; TARGET OF RAPAMYCIN KINASE;

APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; CALU 1 CELL LINE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIVITY; FEEDBACK SYSTEM; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; LUNG CANCER CELL LINE; MDA MB 231 CELL LINE; PROTEIN PHOSPHORYLATION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; MCF-7 CELL LINE; METABOLISM; PHOSPHORYLATION; S PHASE CELL CYCLE CHECKPOINT; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CHROMONES; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; MCF-7 CELLS; MORPHOLINES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RAS PROTEINS; S PHASE; S PHASE CELL CYCLE CHECKPOINTS; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84943765230     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.1080/15384101.2015.1046653     Document Type: Article

References (39)

1. Hung CM, Garcia-Haro L, Sparks CA, Guertin DA. mTOR-dependent cell survival mechanisms. Cold Spring Harb Perspect Biol 2012; 4: a008771; PMID: 23124837.
2. Fingar DC, Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 2004; 23: 3151-71; PMID: 15094765; http://dx. doi. org/10. 1038/sj. onc. 1207542.
3. Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 2012; 21: 297-308; PMID: 22439925; http://dx. doi. org/10. 1016/j. ccr. 2012. 02. 014.
4. Blagosklonny MV. Molecular damage in cancer: an argument for mTOR-driven aging. Aging 2011; 3: 1130-41; PMID: 22246147.
5. Foster DA. Phosphatidic acid signaling to mTOR: signals for the survival of human cancer cells. Biochim Biophys Acta 2009; 1791: 949-55; PMID: 19264150; http://dx. doi. org/10. 1016/j. bbalip. 2009. 02. 009.
6. Sun SY. mTOR kinase inhibitors as potential cancer therapeutic drugs. Cancer Lett 2013; 340: 1-8; PMID: 23792225; http://dx. doi. org/10. 1016/j. canlet. 2013. 06. 017.
7. Gadir N, JacksonDN, Lee E, FosterDA. Defective TGFb signaling sensitizes human cancer cells to rapamycin. Oncogene 2008; 27: 1055-62; PMID: 17700525; http://dx. doi. org/10. 1038/sj. onc. 1210721.
8. Chatterjee A, Mukhopadhyay S, Tung K, Patel D, Foster DA. Rapamycin-induced G1 cell cycle arrest employs both TGF-b and Rb pathways. Cancer Lett 2015; 360: 134-40; PMID: 25659819; http://dx. doi. org/10. 1016/j. canlet. 2015. 01. 043.
9. Le Gendre O, Sookdeo A, Duliepre SA, Utter M, Frias M, Foster DA. Suppression of AKT Phosphorylation restores rapamycin-based synthetic lethality in SMAD4-defective pancreatic cancer cells. Mol Cancer Res 2013; 11: 474-81; PMID: 23443316; http://dx. doi. org/10. 1158/1557-3125. ADVBC-A113.
10. Saqcena M, Menon D, Patel D, Mukhopadhyay S, Chow V, Foster DA. Amino acids and mTOR mediate distinct metabolic checkpoints in mammalian G1 cell cycle. PLoS One 2013; 8: e74157; PMID: 23977397; http://dx. doi. org/10. 1371/journal. pone. 0074157.
11. Foster DA, Gadir N. Can defective TGF-b signaling be an Achilles heel in human cancer?. Chinese J Cancer 2008; 27: 882-4; PMID: 18710627.
12. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL, Sabatini DM. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006; 22: 159-68; PMID: 16603397 http://dx. doi. org/10. 1016/j. molcel. 2006. 03. 029.
13. Toschi A, Lee E, Xu L, Garcia A, Gadir N, Foster DA. Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin. Mol Cell Biol 2009; 29: 1411-20; PMID: 19114562; http://dx. doi. org/10. 1128/MCB. 00782-08.
14. Chen Y, Zheng Y, Foster DA. Phospholipase D confers rapamycin resistance in human breast cancer cells. Oncogene 2003; 22: 3937-42; PMID: 12813467; http://dx. doi. org/10. 1038/sj. onc. 1206565.
15. Fang Y, Vilella-Bach M, Bachmann R, Flanigan A, Chen J. Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Science 2001; 294: 1942-5; PMID: 11729323; http://dx. doi. org/10. 1126/science. 1066015.
16. Yellen P, Saqcena M, Salloum D, Feng J, Preda A, Xu L, Rodrik-Outmezguine V, Foster DA. High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1. Cell Cycle 2011; 10: 3948-56; PMID: 22071574; http://dx. doi. org/10. 4161/cc. 10. 22. 18124.
17. Yellen P, Chatterjee A, Preda A, Foster DA. Inhibition of S6 kinase suppresses the apoptotic effect of eIF4E ablation by inducing TGF-b-dependent G1 cell cycle arrest. Cancer Lett 2013; 333: 239-43; PMID: 23376634; http://dx. doi. org/10. 1016/j. canlet. 2013. 01. 041.
18. Richter JD, Sonenberg N. Regulation of cap-dependent translation by eIF4E inhibitory proteins. Nature 2005; 433: 477-80; PMID: 15690031; http://dx. doi. org/10. 1038/nature03205.
19. Saqcena M, Mukhopadhyay S, Hosny C, Alhamed A, Chatterjee A, Foster DA. Blocking anaplerotic entry of glutamine into the TCA cycle sensitizes K-Ras mutant cancer cells to cytotoxic drugs. Oncogene 2015; 34: 2672-80; PMID: 25023699; http://dx. doi. org/10. 1038/onc. 2014. 207.
20. Salloum D, Mukhopadhyay S, Tung K, Polonetskaya A, Foster DA. Mutant Ras elevates dependence on serum lipids and creates a synthetic lethality for rapamycin. Mol Cancer Ther 2014; 13: 733-41; PMID: 24435447; http://dx. doi. org/10. 1158/1535-7163. MCT-13-0762.
21. Foster DA, Yellen P, Xu L, Saqcena M. Regulation of G1 cell cycle progression: distinguishing the restriction point from a nutrient-sensing cell growth checkpoint (s). Genes Cancer 2010; 1: 1124-31; PMID: 21779436; http://dx. doi. org/10. 1177/1947601910392989.
22. Javanmoghadam-Kamrani S, Keyomarsi K. Synchronization of the cell cycle using lovastatin. Cell Cycle 2008; 7: 2434-40; PMID: 18677105; http://dx. doi. org/10. 4161/cc. 6364.
23. Keyomarsi K, Sandoval L, Band V, Pardee AB. Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res 1991; 51: 3602-9; PMID: 1711413.
24. Alberts AW. Discovery, biochemistry and biology of lovastatin. Am J Cardiology 1988; 62: 10J-5J; PMID: 3055919; http://dx. doi. org/10. 1016/0002-9149(88)90002-1.
25. Pagano M, Pepperkok R, Verde F, Ansorge W, Draetta G. Cyclin A is required at two points in the human cell cycle. EMBO J 1992; 11: 961-71; PMID: 1312467.
26. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006; 66: 1500-8; PMID: 16452206; http://dx. doi. org/10. 1158/0008-5472. CAN-05-2925.
27. Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H, Khuri FR. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005; 65: 7052-8; PMID: 16103051; http://dx. doi. org/10. 1158/0008-5472. CAN-05-0917.
28. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007; 129: 1261-74; PMID: 17604717; http://dx. doi. org/10. 1016/j. cell. 2007. 06. 009.
29. WendelHG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S, Cordon-Cardo C, Pelletier J, Lowe SW. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004; 428: 332-7; PMID: 15029198; http://dx. doi. org/10. 1038/nature02369.
30. Liu P, Begley M, Michowski W, Inuzuka H, Ginzberg M, GaoD, Tsou P, GanW, Papa A, Kim BM. Cell-cycle-regulated activation of Akt kinase by phosphorylation at its carboxyl terminus. Nature 2014; 508: 541-5; PMID: 24670654; http://dx. doi. org/10. 1038/nature13079.
31. Stumpf CR, Moreno MV, Olshen AB, Taylor BS, Ruggero D. The translational landscape of the mammalian cell cycle. Mol Cell 2013; 52: 574-82; PMID: 24120665; http://dx. doi. org/10. 1016/j. molcel. 2013. 09. 018.
32. Andrs M, Korabecny J, Jun D, Hodny Z, Bartek J, Kuca K. Phosphatidylinositol 3-linase (PI3K) and phosphatidylinositol 3-kinase-related kinase (PIKK) inhibitors: importance of the morpholine ring. J Med Chem 2014; 8: 41-71; PMID: 25387153; http://dx. doi. org/10. 1021/jm501026z.
33. DeBerardinis RJ, Cheng T. Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 2010; 29: 313-24; PMID: 19881548; http://dx. doi. org/10. 1038/onc. 2009. 358.
34. Hensley CT, Wasti AT, DeBerardinis RJ. Glutamine and cancer: cell biology, physiology, and clinical opportunities. J Clin Invest 2013; 123: 3678-84; PMID: 23999442; http://dx. doi. org/10. 1172/JCI69600.
35. Chen Y, Rodrik V, Foster DA. Alternative phospholipase D/mTOR survival signal in human breast cancer cells. Oncogene 2005; 24: 672-9; PMID: 15580312; http://dx. doi. org/10. 1038/sj. onc. 1208099.
36. Leontieva OV, Blagosklonny MV. Tumor promoterinduced cellular senescence: cell cycle arrest followed by geroconversion. Oncotarget 2014; 5: 12715-27; PMID: 25587030.
37. Bitterman PB, Polunovsky VA. eIF4E-mediated translational control of cancer incidence. Biochim Biophys acta 2014; Epub ahead of print; PMID: 25263391; http://dx. doi. org/10. 1016/j. bbagrm. 2014. 09. 007.
38. Sonenberg N. eIF4E, the mRNA cap-binding protein: from basic discovery to translational research. Biochem Cell Biol 2008; 86: 178-83; PMID: 18443631; http://dx. doi. org/10. 1139/O08-034.
39. Jackman J, O'Connor PM. Methods for synchronizing cells at specific stages of the cell cycle. Curr Protoc Cell Biol 2001; 8: 8. 3; PMID: 18228388;; 10. 1002/0471143030. cb0803s00.